Suven Life Science gets neuro patent from India, Japan

The patents are valid till 2027 and 2032

Drug firm Suven Life Sciences has been granted a patent each by India and Japan for a drug used in the treatment of neuro-degenerative diseases.

In a BSE filing, Suven Life said it has been granted "one product patent from India and one product patent from Japan corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases".

The patents are valid till 2027 and 2032, respectively, the company added.

The granted claims of the patents… are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s and Schizophrenia.

Venkat Jasti, CEO, Suven Life said, "We are pleased by the grant of these patents to Suven for our pipeline of molecules in CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."